Comparison of 6-Month and Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Biodegradable Polymer Everolimus-Eluting Stent
Table 3
Primary and secondary endpoints between the short-DAPT and prolonged-DAPT groups in the matched population.
Short-DAPT (N = 283)
Prolonged-DAPT (N = 283)
Hazard ratio
Primary endpoint
Mortality, MI, or TVR
19 (7.5)
22 (8.3)
0.87 (0.47–1.60)
0.648
Secondary endpoints
Cardiac mortality, MI, or TVR
16 (6.1)
19 (7.2)
0.84 (0.43–1.64)
0.615
Mortality or MI
8 (3.4)
7 (2.8)
1.16 (0.42–3.20)
0.775
Cardiac mortality or MI
5 (2.0)
4 (1.7)
1.26 (0.34–4.68)
0.733
Mortality
7 (3.0)
5 (2.0)
1.42 (0.45–4.48)
0.547
Cardiac mortality
4 (1.6)
2 (0.9)
2.01 (0.37–10.98)
0.420
MI
1 (0.4)
2 (0.8)
0.50 (0.05–5.54)
0.574
TLR
8 (3.0)
9 (3.3)
0.89 (0.34–2.30)
0.809
TVR
12 (4.5)
16 (5.9)
0.75 (0.36–1.59)
0.455
Stent thrombosis, definite or probable
1 (0.4)
—
—
—
Bleeding, BARC 2, 3, or 5
8 (3.3)
12 (4.4)
0.67 (0.27–1.63)
0.650
Bleeding, TIMI major or minor
7 (2.7)
9 (3.4)
0.80 (0.30–2.14)
0.376
BARC, bleeding academic research consortium; MI, myocardial infarction; TIMI, thrombolysis In myocardial Infarction; TLR, target-lesion revascularization; TVR, target-vessel revascularization.
